Abstract
The congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic syndromes with a wide symptomatology and severity. They all stem from deficient N-glycosylation of proteins. To date the group contains 18 different subtypes: 12 of Type I (disrupted synthesis of the lipid-linked oligosaccharide precursor) and 6 of Type II (malfunctioning trimming/processing of the protein-bound oligosaccharide). Main features of CDG involve psychomotor retardation; ataxia; seizures; retinopathy; liver fibrosis; coagulopathies; failure to thrive; dysmorphic features, including inverted nipples and subcutaneous fat pads; and strabismus. No treatment currently is available for the vast majority of these syndromes (CDG-Ib and CDG-IIc are exceptions), even though attempts to synthesize drugs for the most common subtype, CDG-Ia, have been made. In this review we will discuss the individual syndromes, with focus on their neuronal involvement, available and possible treatments, and future directions.
Original language | English |
---|---|
Pages (from-to) | 254-63 |
Journal | NeuroRx |
Volume | 3 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2006 |
Bibliographical note
The information about affiliations in this record was updated in December 2015.The record was previously connected to the following departments: Cell and Matrix Biology (LUR000002), Matrix biology (013212025)
Subject classification (UKÄ)
- Cell and Molecular Biology
Free keywords
- N-glycosylation
- CDG
- mannose
- synthetic compounds
- brain glycosylation
- ataxia
- cerebellar hypoplasia
- seizures